Trial reportAntimicrobial agents and chemotherapy2012
Pharmacokinetics of doxycycline in adults with cystic fibrosis.
Trial report in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01323101 (Effect of Doxycycline on Sputum Biomarkers of Inflammation and Lung Epithelial Repair in Patients With Cystic Fibrosis.), which is not on this map. Cited by 26 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Doxycycline on Sputum Biomarkers of Inflammation and Lung Epithelial Repair in Patients With Cystic Fibrosis.
Who cites it
26 citing papers in PubMed, 4 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.The Cochrane database of systematic reviews · 2025Pooled it
- Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis.The Cochrane database of systematic reviews · 2021Pooled it
- Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis.The Cochrane database of systematic reviews · 2016Pooled it
- Oral anti-pseudomonal antibiotics for cystic fibrosis.The Cochrane database of systematic reviews · 2016Pooled it
- Trial
- Target site pharmacokinetics of doxycycline for rosacea in healthy volunteers is independent of the food effect.British journal of clinical pharmacology · 2018Trial
- Population pharmacokinetics of mycophenolic acid in lung transplant recipients with and without cystic fibrosis.European journal of clinical pharmacology · 2015Trial
- Antimicrobial Pharmacokinetic and Pharmacodynamic Considerations in Special Populations: A Call to Action.Open forum infectious diseases · 2026Review
- Switching From Dual to Monotherapy for Gonorrhea is Associated With a Halving of Gonococcal Resistance to Azithromycin-A Modelling Study of MSM in Belgium.Open forum infectious diseases · 2025Article
- Doxycycline to treat levodopa-induced dyskinesias in Parkinson's disease: a preliminary study.Arquivos de neuro-psiquiatria · 2023Article
- Green ecofriendly electrochemical sensing platform for the sensitive determination of doxycycline.Heliyon · 2023Article
- Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis.Clinical pharmacokinetics · 2021Review
- Structurally nanoengineered antimicrobial peptide polymers: design, synthesis and biomedical applications.World journal of microbiology & biotechnology · 2021Review
- Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review.Drug safety · 2021Article
- Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.Clinical pharmacokinetics · 2021Review
- In Vitro Comparative Quality Assessment of Different Brands of Doxycycline Hyclate Finished Dosage Forms: Capsule and Tablet in Jimma Town, South-West Ethiopia.Advances in pharmacological and pharmaceutical sciences · 2021Article
- Immunotherapy of Autoimmune Diseases with Nonantibiotic Properties of Tetracyclines.Immune network · 2020Review
- In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2.Molecules (Basel, Switzerland) · 2020Article
- Scrub Typhus and the Misconception of Doxycycline Resistance.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Review
- A Validated Volumetric Absorptive Microsampling-Liquid Chromatography Tandem Mass Spectrometry Method to Quantify Doxycycline Levels in Urine: An Application to Monitor the Malaria Chemoprophylaxis Compliance.Journal of analytical methods in chemistry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Cystic fibrosis (CF) is characterized by a chronic neutrophilic inflammatory response resulting in airway remodeling and progressive loss of lung function. Doxycycline is a tetracycline antibiotic that inhibits matrix metalloproteinase 9, a protease known to be associated with the severity of lung disease in CF. The pharmacokinetics of doxycycline was investigated during the course of a clinical trial to evaluate the short-term efficacy and safety in adults with CF. Plasma samples were obtained from 14 patients following a single intravenous dose and after 2 and 4 weeks of oral administration of doses ranging from 40 to 200 mg daily. The data were analyzed using noncompartmental and compartmental pharmacokinetics. The maximum concentration of drug in serum (C(max)) and area under the concentration-time curve from 0 h to infinity (AUC(0-∞)) values ranged from 1.0 to 3.16 mg/liter and 15.2 to 47.8 mg/liter × h, respectively, following single intravenous doses of 40 to 200 mg. C(max) and time to maximum concentration of drug in serum (T(max)) values following multiple-dose oral administration ranged from 1.15 to 3.04 mg/liter and 1.50 to 2.33 h, respectively, on day 14 and 1.48 to 3.57 mg/liter and 1.00 to 2.17 on day 28. Predose sputum/plasma concentration ratios on days 14 and 28 ranged from 0.33 to 1.1 (mean, 0.71 ± 0.33), indicating moderate pulmonary penetration. A 2-compartment model best described the combined intravenous and oral data. Absorption was slow and delayed (absorption rate constant [K(a)], 0.414 h(-1); lag time, 0.484 h) but complete (bioavailability [F], 1.16). The distribution and elimination half-lives were 0.557 and 18.1 h, respectively. Based on these data, the plasma concentrations at the highest dose, 200 mg/day, are in the range reported to produce anti-inflammatory effects in vivo and should be evaluated in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.